Marc Odrich
Plus aucun poste en cours
Fortune : 2 M $ au 31/05/2024
Profil
Marc Odrich is currently the Chief Medical Officer & Director at TearSolutions, Inc., the Director at CXL Ophthalmics LLC, the Chief Medical Officer at LENZ Therapeutics, Inc., and an Associate Professor at the University of Virginia.
He previously worked as the Medical Director at VISX, Inc. Dr. Odrich holds a doctorate degree from Columbia University College of Physicians & Surgeons.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,39% | 21/03/2024 | 99 599 ( 0,39% ) | 2 M $ | 31/05/2024 |
Postes actifs de Marc Odrich
| Sociétés | Poste | Début |
|---|---|---|
TearSolutions, Inc.
 TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Corporate Officer/Principal | - |
CXL Ophthalmics LLC
 CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Directeur/Membre du Conseil | - |
| University of Virginia | Corporate Officer/Principal | - |
Anciens postes connus de Marc Odrich
| Sociétés | Poste | Fin |
|---|---|---|
| VISX, Inc. | Directeur Technique/Scientifique/R&D | - |
Formation de Marc Odrich
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
TearSolutions, Inc.
TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Health Technology |
| VISX, Inc. | |
CXL Ophthalmics LLC
CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Health Services |
